Maha Radhakrishnan - 08 Mar 2024 Form 4 Insider Report for Alto Neuroscience, Inc. (ANRO)

Reporting relationship: Director
Issuer ticker: ANRO
Reported as of: 08 Mar 2024
Net transaction value: +$16,239
SEC form: 4
Accepted by SEC: 12 Mar 2024, 16:49:43 UTC
Next SEC filing: 03 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Erin R. McQuade, Attorney-in-Fact

Key filing fact

Maha Radhakrishnan filed Form 4 for Alto Neuroscience, Inc. (ANRO) on 12 Mar 2024.

Key facts

This page summarizes Maha Radhakrishnan's Form 4 filing for Alto Neuroscience, Inc. (ANRO).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 12 Mar 2024, 16:49.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: +$16,239.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ANRO transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +30,574
Change %
Price: $0.000000
Shares after: 30,574
Date: 08 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,574
Exercise price: $13.76
Footnotes: F1

ANRO transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $16,239
Shares: +1,590
Change %
Price: $10.21^*
Shares after: 1,590
Date: 08 Mar 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,590
Exercise price: $13.76
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares underlying the option shall vest in 36 equal monthly installments commencing on April 8, 2024, subject to the Reporting Person's continuous service through each vesting date.

Footnote F2

123 shares underlying the option shall vest on March 31, 2024, and 489 shares underlying the option shall vest on each of June 30, 2024, September 30, 2024 and December 31, 2024, subject to the Reporting Person's continuous service through each such vesting date.

Footnote F3

This option was issued to the Reporting Person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of retainer fees of $16,263.74.